Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Cancer Med ; 10(15): 5051-5061, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-34245128

RESUMO

BACKGROUND: Long-term breast cancer survivors are at risk for cardiotoxicity after treatment, but there is insufficient evidence to provide long-term (~10 years) cardiovascular disease (CVD) screening recommendations. We sought to evaluate a tri-modality CVD screening approach. METHODS: This single-arm, feasibility study enrolled 201 breast cancer patients treated ≥6 years prior without CVD at diagnosis. Patients were sub-grouped: cardiotoxic (left-sided) radiation (RT), cardiotoxic (anthracycline-based) chemotherapy, both cardiotoxic chemotherapy and RT, and neither cardiotoxic treatment. Patients underwent electrocardiogram (EKG), transthoracic echocardiogram with strain (TTE with GLS), and coronary artery calcium computed tomography (CAC CT). The primary endpoint was preclinical or clinical CVD. RESULTS: Median age was 50 (29-65) at diagnosis and 63 (37-77) at imaging; median interval was 11.5 years (6.7-14.5). Among sub-groups, 44% had no cardiotoxic treatment, 31.5% had cardiotoxic RT, 16% had cardiotoxic chemotherapy, and 8.5% had both. Overall, 77.6% showed preclinical and/or clinical CVD and 51.5% showed clinical CVD. Per modality, rates of any CVD and clinical CVD were, respectively: 27.1%/10.0% on EKG, 50.0%/25.3% on TTE with GLS, and 50.8%/45.8% on CAC CT. No statistical difference was seen among the treatment subgroups (NS, χ2 test, p = 0.58/p = 0.15). CONCLUSION: This study identified a high incidence of CVD in heterogenous long-term breast cancer survivors, most >10 years post-treatment. Over half had clinical CVD findings warranting follow-up and/or intervention. Each imaging test independently contributed to the detection rate. This provides early evidence that long-term cardiac screening may be of value to a wider group of breast cancer survivors than previously recognized.


Assuntos
Sobreviventes de Câncer , Cardiotoxicidade/diagnóstico por imagem , Neoplasias Unilaterais da Mama/tratamento farmacológico , Neoplasias Unilaterais da Mama/radioterapia , Adulto , Idoso , Antraciclinas/efeitos adversos , Antineoplásicos/efeitos adversos , Cardiotoxicidade/epidemiologia , Cardiotoxicidade/etiologia , Doenças Cardiovasculares/diagnóstico , Doenças Cardiovasculares/epidemiologia , Doença das Coronárias/diagnóstico por imagem , Doença das Coronárias/epidemiologia , Ecocardiografia/métodos , Eletrocardiografia/métodos , Estudos de Viabilidade , Feminino , Coração/efeitos dos fármacos , Coração/efeitos da radiação , Humanos , Pessoa de Meia-Idade , Radioterapia/efeitos adversos , Análise de Regressão , Fatores de Risco , Fatores de Tempo , Tomografia Computadorizada por Raios X , Calcificação Vascular/diagnóstico por imagem , Calcificação Vascular/epidemiologia
2.
Pharm Pat Anal ; 5(6): 401-406, 2016 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-27805847

RESUMO

This article deals with compulsory licensing scenarios in India, provides a background of relevant provisions in the Patents Act and examines how these provisions are Trade-Related Aspects of Intellectual Property Rights compliant. This article further discusses the procedure followed by India in granting a compulsory license, provides an overview of compulsory license applications filed in India to date and judicial precedence regarding the same. This article also highlights how compulsory licensing is a great safeguard that balances the interests of the innovators and the public at large.


Assuntos
Licenciamento/legislação & jurisprudência , Patentes como Assunto/legislação & jurisprudência , Indústria Farmacêutica/legislação & jurisprudência , Humanos , Índia
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa